Regular Risk Assessment in Pulmonary Arterial Hypertension - A Whistleblower for Hidden Disease Progression

Overview

Journal Acta Cardiol Sin

Date 2022 Mar 11

PMID 35273432

Authors

Shu-Hao Wu

Yih-Jer Wu

Affiliations

Soon will be listed here.

Abstract

Despite developments in the treatment of pulmonary arterial hypertension, timely treatment is seldom achieved, and hidden progression is not uncommonly disguised as a seemingly "stable" condition. Appropriate risk assessment tools facilitate goal-oriented treatment strategies. This article aimed to review the development of these risk assessment tools including early assessment equations/scores, European guidelines-based risk assessment scores, and tools derived from the United States nationwide registry. A stepwise and regular approach with these assessment tools in clinical practice is highly recommended for timely treatment escalation to stop disease progression early. In this review, a practical and recommended algorithm of these assessment tools is also provided.

Citing Articles

Application of homocysteine as a non-invasive and effort-free measurements for risk assessment of patients with pulmonary hypertension.

Wang M, Chi P, Cheng C, Huang W, Chen L Cardiol J. 2023; 31(2):285-299.

PMID: 37772357 PMC: 11076026. DOI: 10.5603/cj.92813.

Long-Term Experience and Safety of Transitioning from Subcutaneous Treprostinil to Oral Selexipag in the High-Risk Pulmonary Hypertension Patient: A Case Report.

Ting Y, Yu M, Wu Y, Wu S Acta Cardiol Sin. 2023; 39(3):492-496.

PMID: 37229336 PMC: 10203720. DOI: 10.6515/ACS.202305_39(3).20230130A.

Pulmonary Hypertension, an Evolutional Disease with Multidisciplinary Team Management.

Chiu Y, Wu Y Acta Cardiol Sin. 2023; 39(2):209-212.

PMID: 36911545 PMC: 9999180. DOI: 10.6515/ACS.202303_39(2).20230208A.

Pulse Wave Analysis Predicts Invasive Hemodynamics in Pre-Capillary Pulmonary Hypertension.

Liu Y, Wu S, Tsai C, Sun F, Hou C, Yeh H Acta Cardiol Sin. 2023; 39(2):319-330.

PMID: 36911541 PMC: 9999185. DOI: 10.6515/ACS.202303_39(2).20220826A.

References

Cogswell R, Pritzker M, De Marco T . Performance of the REVEAL pulmonary arterial hypertension prediction model using non-invasive and routinely measured parameters. J Heart Lung Transplant. 2014; 33(4):382-7. DOI: 10.1016/j.healun.2013.12.015. View

Badagliacca R, Papa S, Manzi G, Miotti C, Luongo F, Sciomer S . Usefulness of Adding Echocardiography of the Right Heart to Risk-Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension. JACC Cardiovasc Imaging. 2020; 13(9):2054-2056. DOI: 10.1016/j.jcmg.2020.04.005. View

Galie N, Humbert M, Vachiery J, Gibbs S, Lang I, Torbicki A . 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):.... Eur Heart J. 2015; 37(1):67-119. DOI: 10.1093/eurheartj/ehv317. View

Deng X, Jin B, Li S, Li Y, Zhou H, Wu Y . Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study. Clin Respir J. 2019; 13(11):693-699. PMC: 6899897. DOI: 10.1111/crj.13076. View

Benza R, Miller D, Gomberg-Maitland M, Frantz R, Foreman A, Coffey C . Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010; 122(2):164-72. DOI: 10.1161/CIRCULATIONAHA.109.898122. View

Ghofrani H, Galie N, Grimminger F, Grunig E, Humbert M, Jing Z . Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013; 369(4):330-40. DOI: 10.1056/NEJMoa1209655. View

Thenappan T, Glassner C, Gomberg-Maitland M . Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest. 2011; 141(3):642-650. DOI: 10.1378/chest.11-0969. View

Liu B, Wu W, Zeng Q, Liu Z, Niu L, Tian Y . Comparison of the capability of risk stratification evaluation between two- and three-dimensional speckle-tracking strain in pre-capillary pulmonary hypertension. Pulm Circ. 2020; 9(4):2045894019894525. PMC: 6935885. DOI: 10.1177/2045894019894525. View

Benza R, Farber H, Frost A, Ghofrani H, Gomez-Sanchez M, Langleben D . REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival. J Heart Lung Transplant. 2017; 37(4):513-519. DOI: 10.1016/j.healun.2017.11.006. View

10.

Benza R, Gomberg-Maitland M, Miller D, Frost A, Frantz R, Foreman A . The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2011; 141(2):354-362. DOI: 10.1378/chest.11-0676. View

11.

Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G . Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. Eur Respir J. 2017; 50(2). DOI: 10.1183/13993003.00889-2017. View

12.

Humbert M, Sitbon O, Yaici A, Montani D, OCallaghan D, Jais X . Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010; 36(3):549-55. DOI: 10.1183/09031936.00057010. View

13.

Boucly A, Weatherald J, Humbert M, Sitbon O . Risk assessment in pulmonary arterial hypertension. Eur Respir J. 2018; 51(3). DOI: 10.1183/13993003.00279-2018. View

14.

Kjellstrom B, Lindholm A, Ostenfeld E . Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: Ready for Clinical Practice and Guidelines?. Curr Heart Fail Rep. 2020; 17(5):181-191. PMC: 7495997. DOI: 10.1007/s11897-020-00479-7. View

15.

Li X, Sun X, Huang Y, Wang Y, Yang X, Wang J . Simplified risk stratification for pulmonary arterial hypertension associated with connective tissue disease. Clin Rheumatol. 2019; 38(12):3619-3626. DOI: 10.1007/s10067-019-04690-3. View

16.

Bredfelt A, Radegran G, Hesselstrand R, Arheden H, Ostenfeld E . Increased right atrial volume measured with cardiac magnetic resonance is associated with worse clinical outcome in patients with pre-capillary pulmonary hypertension. ESC Heart Fail. 2018; 5(5):864-875. PMC: 6165945. DOI: 10.1002/ehf2.12304. View

17.

Amsallem M, Sweatt A, Aymami M, Kuznetsova T, Selej M, Lu H . Right Heart End-Systolic Remodeling Index Strongly Predicts Outcomes in Pulmonary Arterial Hypertension: Comparison With Validated Models. Circ Cardiovasc Imaging. 2017; 10(6. PMC: 5527228. DOI: 10.1161/CIRCIMAGING.116.005771. View

18.

Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M . Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation. 2017; 137(7):693-704. DOI: 10.1161/CIRCULATIONAHA.117.029254. View

19.

Benza R, Miller D, Foreman A, Frost A, Badesch D, Benton W . Prognostic implications of serial risk score assessments in patients with pulmonary arterial hypertension: a Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) analysis. J Heart Lung Transplant. 2014; 34(3):356-61. DOI: 10.1016/j.healun.2014.09.016. View

20.

Sayegh A, Silva B, Ferreira E, Ramos R, Fisher J, Nery L . Clinical utility of ventilatory and gas exchange evaluation during low-intensity exercise for risk stratification and prognostication in pulmonary arterial hypertension. Respirology. 2020; 26(3):264-272. DOI: 10.1111/resp.13959. View